SEC 13F Intelligence

Managers / Q2 2023 · view latest →

Endurant Capital Management LP

CIK 0001633055 · 66 BOVET ROAD, SUITE 353, SAN MATEO, CA, 94402 · 650-539-5905

Reported Value
$115M
Q2 2023
Positions
34
Filings on Record
24
2019–present window
Filed
Aug 14, 2023
original filing

Summary

Endurant Capital Management LP reported $115M in U.S.-listed holdings across 34 positions for Q2 2023.

Its largest position, Laboratory Corp Amer, represents 6.9% of the portfolio.

Compared with Q1 2023, the fund opened 12 new positions and exited 28.

Portfolio Metrics

Turnover
+34.7%
vs prior filed quarter
Top-10 Concentration
+43.9%
share of reported value
Largest Position
+6.9%
Laboratory Corp Amer
New / Exited
12 / 28
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $189MQ4 ’18Q1 ’19: $253MQ2 ’19: $254MQ3 ’19: $279MQ3 ’19Q4 ’19: $317MQ1 ’20: $221MQ2 ’20: $1.8BQ2 ’20Q3 ’20: $338MQ4 ’20: $277MQ1 ’21: $384MQ1 ’21Q2 ’21: $364MQ3 ’21: $439MQ4 ’21: $414MQ4 ’21Q1 ’22: $380MQ2 ’22: $285MQ3 ’22: $307MQ3 ’22Q4 ’22: $246MQ1 ’23: $195MQ2 ’23: $115MQ2 ’23Q3 ’23: $111MQ4 ’23: $17MQ1 ’24: $0Q1 ’24filingsflow.com

Portfolio Composition

By security type
Common Stock: 55.9%ETP: 23.7%Other: 12.2%ADR: 6.5%REIT: 1.7%
  • Common Stock · 55.9% · $64M
  • ETP · 23.7% · $27M
  • Other · 12.2% · $14M
  • ADR · 6.5% · $7M
  • REIT · 1.7% · $2M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SPDR S&P 500 ETF TRNEW+6.1K6.1K+$27M$27M
AG8AGILENT TECHNOLOGIES INCNEW+45.8K45.8K+$6M$6M
IQVIQVIA HLDGS INCNEW+19.2K19.2K+$4M$4M
BSXBOSTON SCIENTIFIC CORPNEW+61.0K61.0K+$3M$3M
CAHCARDINAL HEALTH INCNEW+31.7K31.7K+$3M$3M
MEDTRONIC PLCNEW+27.2K27.2K+$2M$2M
VENVENTAS INCNEW+41.6K41.6K+$2M$2M
BRKRBRUKER CORPNEW+15.2K15.2K+$1M$1M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2023

30 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1LABORATORY CORP AMER HLDGSCOM NEW6.86%$8M32.6K
2CITHE CIGNA GROUPhistory →COM6.32%$7M25.8K
3MRKMERCK & CO INChistory →COM4.97%$6M49.3K
4AG8AGILENT TECHNOLOGIES INChistory →COM4.80%$6M45.8K
5THCTENET HEALTHCARE CORPhistory →COM NEW4.12%$5M58.0K
6AZNNASTRAZENECA PLChistory →SPONSORED ADR3.80%$4M60.8K
7IQVIQVIA HLDGS INChistory →COM3.76%$4M19.2K
8BMRNBIOMARIN PHARMACEUTICAL INChistory →COM3.30%$4M43.6K
9BDXBECTON DICKINSON & COhistory →COM3.08%$4M13.4K
10BSXBOSTON SCIENTIFIC CORPhistory →COM2.88%$3M61.0K
11CAHCARDINAL HEALTH INChistory →COM2.62%$3M31.7K
12QIAGEN NVSHS NEW2.47%$3M62.7K
13ELVELEVANCE HEALTH INChistory →COM2.19%$3M5.6K
14MEDTRONIC PLCSHS2.09%$2M27.2K
15EHCENCOMPASS HEALTH CORPhistory →COM1.93%$2M32.7K
16VENVENTAS INChistory →COM1.72%$2M41.6K
17OCULOCULAR THERAPEUTIX INChistory →COM1.66%$2M368.4K
18IM8NINSMED INChistory →COM PAR $.011.46%$2M79.5K
19ZTSZOETIS INChistory →CL A1.15%$1M7.6K
20BRKRBRUKER CORPCOM0.98%$1M15.2K
21ARGXARGENX SESPONSORED ADR0.87%$999,6572.6K
22BLUEBIRD BIO INCCOM0.81%$925,941281.4K
23SELECTA BIOSCIENCES INCCOM0.67%$768,480686.1K
24ADAPYADAPTIMMUNE THERAPEUTICS PLCSPONDS ADR0.66%$759,460821.0K
25ACHCACADIA HEALTHCARE COMPANY INCOM0.64%$728,9459.2K
26ETNBGBP89BIO INCCOM0.48%$554,89429.3K
27KIDSORTHOPEDIATRICS CORPCOM0.41%$470,99310.7K
28MASI*MASIMO CORPCOM0.41%$468,9682.9K
29OLMAOLEMA PHARMACEUTICALS INCCOM0.32%$362,86240.2K
30VKTXVIKING THERAPEUTICS INCCOM0.29%$336,42220.8K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2024$01May 7, 202413F-HRchanges · EDGAR ↗
Q4 2023$17M25Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$111M43Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$115M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$195M50May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$246M55Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$307M49Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$285M50Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$380M63May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$414M68Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$439M53Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M57Aug 27, 2021RESTATEMENTchanges · EDGAR ↗
Q1 2021$384M61May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$277M52Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$338M60Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.8B56Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$221M51May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$317M54Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$279M49Nov 25, 2019RESTATEMENTchanges · EDGAR ↗
Q2 2019$254M50Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$253M70May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$189M48Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.